Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bene-arzneimittel gmbh - pentosan polysulfate sodium - Ċistite, interstizjali - uroloġiċi - elmiron huwa indikat għat-trattament ta 'sindromu tal-uġigħ tal-bużżieqa kkaratterizzat minn glomerulazzjonijiet jew leżjonijiet ta' hunner f'adulti b'uġigħ moderat għal sever, urġenza u frekwenza ta 'micturition.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, bromur tal-umeclidinium, trifenatate tal-vilanterol - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - elebrato ellipta hija indikata bħala trattament manutenzjoni fil-pazjenti adulti ma moderat severi kronika eliminat pulmonari marda (copd) li m'humiex ittrattati adegwatament mill-għaqda tal-corticosteroid bin-nifs u a twila u jaġixxu β2-agonist.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - naloxone hydrochloride dihydrate - disturbi relatati ma 'opjojdi - il-prodotti terapewtiċi l-oħra kollha - nyxoid huwa maħsub għal amministrazzjoni immedjata bħala terapija ta 'emerġenza għal doża eċċessiva magħrufa jew suspettata ta' opjojdi kif manifestat mid-depressjoni tas-sistema nervuża respiratorja u / jew ċentrali kemm f'ambjenti mhux mediċi kif ukoll fil-kura tas-saħħa. nyxoid is indicated in adults and adolescents aged 14 years and over. nyxoid is not a substitute for emergency medical care.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline trading services - fluticasone furoate, bromur tal-umeclidinium, trifenatate tal-vilanterol - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - trelegy ellipta hija indikata bħala trattament manutenzjoni fil-pazjenti adulti ma moderat severi kronika eliminat pulmonari marda (copd) li m'humiex ittrattati adegwatament mill-għaqda tal-corticosteroid bin-nifs u a twila u jaġixxu β2-agonist.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - newtropenja - immunostimulanti, - biex inaqqas id-dewmien ta 'newtropenja u l-inċidenza ta' newtropenja bid-deni minħabba l-kimoterapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - newtropenja - immunostimulanti, - tnaqqis fit-tul tal-neutropenia u l-inċidenza tal-marda bid-deni neutropenia fil-pazjenti adulti ttrattati ċitotossiċi chemotherapy għall-malignancy (bl-eċċezzjoni ta ' kronika myeloid lewċemja u myelodysplastic sindromi).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, bromur tal-umeclidinium, trifenatate tal-vilanterol - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - temybric ellipta huwa indikat bħala kura ta 'manteniment f'pazjenti adulti b'indeboliment moderat jew sever tal-marda pulmonari ostruttiva kronika (copd) li ma jkunux qed jiġu kkurati b'taħlita ta' kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2-agonist jew kombinazzjoni ta taġixxi fit-tul β2-agonist u li jaħdem fit-tul muskariniċi antagonist (għall-effetti fuq il-kontroll tas-sintomi u l-prevenzjoni tal-aggravar tal-attakki ara sezzjoni 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmoloġiċi - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaċċini - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.